View Clinical Trial (Medical Research Study)

A Phase 1 Study in Patients With Advanced Cancer - NCT01115790-(Clinical Trial 623044)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Houston
State:  
TX
Zip Code:
Conditions: Advanced Cancer - Non Small Cell Lung Cancer - Colorectal Cancer - Ovarian Cancer
Purpose: The primary purpose of this study is to evaluate the safety and toxicity of LY2606368 (an inhibitor of checkpoint kinase 1[chk 1]) in patients with advanced or metastatic cancer. A dose regimen that may be used in a future phase 2 study will also be determined.
Study summary:
Criteria: Inclusion Criteria: - Must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed - Part A: Must have diagnosis of cancer that is advanced or metastatic Part B: Must have diagnosis of metastatic ovarian cancer, metastatic or recurrent non small cell lung cancer or metastatic colorectal cancer - Must have discontinued previous treatments for cancer and recovered from the acute effects of that therapy - Must be available during the duration of the study and willing to follow the study procedures - If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug - If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 7 days of the first dose of study drug and must not be breast feeding Exclusion Criteria: - Must not have taken an unapproved drug as treatment for any indication within the last 28 days prior to starting study treatment - Must not have an active symptomatic fungal, bacterial or viral infection, including HIV or Hepatitis A, B, or C - Must not have a serious heart condition, such as congestive heart failure, unstable angina pectoris, or heart attack within the last three months - Must not have systolic blood pressure < 90 mmHg or recurrent symptomatic orthostatic hypotension - Must not have a family history of long QTc syndrome or be taking drugs known to cause QTc prolongation or Torsades de Pointes - Must not have a serotonin-secreting carcinoid tumor or a prior history of drug-induced serotonin syndrome - Must not have acute leukemia - Must not be chronically taking beta blockers
Study is available at: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Houston, TX
United States

Primary Contact:
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Phone: 1-317-615-4559
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.